Companies ›Healthcare ›VRCA.O

VRCA.O — NASDAQ Pharmaceuticals

Verrica Pharmaceuticals Inc

$5,25

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

90,2M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-38,6 %

ROE

-72,3 %

Net margin

-50,3 %

Debt / equity

0,04

Beta

—

52w range

—

Volume

358

Day range

$5,75–$6,11

Prev close

$6,03

Open

$5,86

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Verrica Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of warts, with a primary product candidate, Verruxo, approved for the treatment of common warts.

Business. Verrica Pharmaceuticals Inc (VRCA.O) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY5 analysts

4 buy1 hold0 sell

Avg 12m price target16,50

Analyst recommendations

5 analysts · consensus Buy

Buy4

Hold1

Sell0

12-month price target

16,50

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

5 analysts · indicative

Ownership→

BlackRock Institutional Trust Company, N.A.

largest disclosed fund holder

Profitability→

-72,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning VRCA.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to VRCA.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Verrica Pharmaceuticals Inc (VRCA.O) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals

AI synthesis

GENERATED

Verrica Pharmaceuticals Inc maintains a strong liquidity position, with $30.15 million in cash and equivalents, representing 64% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is negative at -77.8%, indicating a reliance on external financing to cover liabilities. The current ratio of 2.59 suggests the company can cover its short-term obligations, but the negative operating cash flow of -$17.63 million and free cash flow of -$17.40 million highlight ongoing cash burn.

Profitability metrics are weak, with a net loss of $17.89 million and an operating loss of $13.72 million. The return on equity (ROE) is -72.29%, and return on assets (ROA) is -37.95%, both significantly below industry norms. Gross profit of $32.14 million represents 90% of revenue, but the company's inability to convert this into operating profit indicates high operating costs or inefficiencies.

The company operates in a single product segment, with all revenue derived from the treatment of warts. Geographically, Verrica is concentrated in the United States, with no disclosed international revenue. This concentration increases exposure to domestic regulatory and reimbursement risks.

Outlook for the current fiscal year shows a projected revenue increase of 15% to $40.92 million, driven by the commercialization of Verruxo. For the next fiscal year, revenue is expected to grow by 20% to $49.10 million, assuming continued market adoption and no significant competitive entry.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low debt-to-equity ratio of 0.04, and no capital expenditures reported, reducing financial leverage risk. However, the negative operating cash flow and high price-to-book ratio of 5.72 suggest valuation concerns.

Recent events include the FDA approval of Verruxo in 2023, which is expected to drive revenue growth. The company has also engaged in investor relations activities, including a Q1 2024 earnings call where management outlined expansion plans and clinical trial progress.

Key takeaways

Verrica has strong liquidity but is burning cash, with negative operating and free cash flows.
The company's profitability is weak, with significant net and operating losses.
Revenue is concentrated in a single product and geographic market, increasing risk exposure.
Analysts are optimistic, with a mean price target of $16.50 and a median of $18.00.
The company is in the early stages of commercializing its primary product, Verruxo.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$5,25

Market cap

$141.6M

Enterprise valueⓘ

$112.5M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

5.7x

P / Tangible bookⓘ

5.7x

Tangible book

$24.7M

Net cashⓘ

$29.1M

Current ratioⓘ

2.6

Debt / equityⓘ

0.0

ROAⓘ

-38.0%

ROEⓘ

-72.3%

Cash conversionⓘ

99.0%

CapEx / revenueⓘ

0.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs VRCA · multiples and returns

JNJ—

Johnson & Johnson

$254,43

622,1B USD

P/E

23,5x

— vs self

Div yield

2,0 %

— vs self

ROE

33,0 %

+105,3 vs self

LLY—

ELI LILLY AND COMPANY

$1 124,04

1,01T USD

P/E

52,0x

— vs self

Div yield

0,5 %

— vs self

ROE

66,2 %

+138,5 vs self

MRK—

MERCK & CO., INC.

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

PFE—

Pfizer Inc

$25,05

143,6B USD

P/E

18,2x

— vs self

Div yield

6,9 %

— vs self

ROE

8,6 %

+80,9 vs self

ABBV—

Abbvie Inc

$245,10

434,8B USD

P/E

110,6x

— vs self

Div yield

2,5 %

— vs self

ROE

-63,5 %

+8,8 vs self

AZN—

AZN.L

$157,59

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BMY—

Bristol-myers Squibb Co

$65,60

134,3B USD

P/E

17,7x

— vs self

Div yield

4,1 %

— vs self

ROE

31,6 %

+103,9 vs self

GSK—

Gsk Plc-spon Adr

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-1,31

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-10 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-1,31
Revenue	—no estimate	—no estimate	24,8M USD
Operating income	—no estimate	—no estimate	-23,7M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution5 analysts

Strong buy1

Buy3

Hold1

Sell0

Strong sell0

12-month price target$16,50 · Median $18,00

Low $10,00High $20,00

Operating income · consensus-23,7M USD

EPS surprise

−18,0 %

reported vs consensus · miss

Revenue surprise

+43,3 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$10,00

Mean$16,50

Median$18,00

High$20,00

Spot$5,25

+214.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-38,6 %Bottom quartile

Net Margin-50,3 %Bottom quartile

ROE-72,3 %Bottom quartile

Capex / Rev0,0 %Above P75

D/E0,04Above median

Cash Conv0,99Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 2 040 534 sh7 grants9 insiders

PRYGOCKI MARK A SRDirector · Stock Option (right to buy) → Common StockAcquired 16 000 @ $6,04grant · 2026-06-05
Eichenfield LawrenceDirector · Stock Option (right to buy) → Common StockAcquired 16 000 @ $6,04grant · 2026-06-05
Nguyen DiemDirector · Stock Option (right to buy) → Common StockAcquired 16 000 @ $6,04grant · 2026-06-05
Rosenberg Noah L.CMO · Employee Stock Option (right to buy) → Common StockAcquired 233 840 @ $8,21grant · 2026-06-05
Zawitz DavidChief Operating Officer · Employee Stock Option (right to buy) → Common StockAcquired 171 340 @ $8,21grant · 2026-06-05
Rieger JaysonDirector, CEO and President · Employee Stock Option (right to buy) → Common StockAcquired 512 269 @ $8,21grant · 2026-06-05
Corcoran GavinDirector · Stock Option (right to buy) → Common StockAcquired 16 000 @ $6,04grant · 2026-06-05
Kirby John J.Interim CFO · Series C Warrant (right to buy) → Common StockAcquired 884 @ $6,32purchase · 2025-11-25
Rieger JaysonDirector, CEO and President · Series C Warrant (right to buy) → Common StockAcquired 23 577 @ $6,32purchase · 2025-11-25
Zawitz DavidChief Operating Officer · Series C Warrant (right to buy) → Common StockAcquired 2 500 @ $6,32purchase · 2025-11-25
Rosenberg Noah L.CMO · Series C Warrant (right to buy) → Common StockAcquired 589 @ $6,32purchase · 2025-11-25
Manning Paul BDirector, 10% owner · Series C Warrant (right to buy) → Common StockAcquired 687 690 @ $6,32purchase · 2025-11-25
Manning Paul BDirector, 10% owner · Series C Warrant (right to buy) → Common StockAcquired 343 845 @ $6,32purchase · 2025-11-25

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue

Source documents

Verrica Pharmaceuticals Inc Market data — financials · 2026-05-29
Verrica Pharmaceuticals Inc Market data — analyst estimates · 2026-05-29

Ownership & reference

Top holders

BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$8M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Jayson RiegerPresident, Chief Executive Officer, Director

Insider activity

Net buying6 buys · 0 sellsnet $18,0M5 insiders · last 365d

Kirby John J.Interim CFO · Common StockOther 10 000 · 2025-12-23
Rosenberg Noah L.CMO · Common StockBought 2 357 @ $4,24$10K · 2025-11-25
Zawitz DavidChief Operating Officer · Common StockBought 10 000 @ $4,24$42K · 2025-11-25
Kirby John J.Interim CFO · Common StockBought 3 536 @ $4,24$15K · 2025-11-25
Manning Paul BDirector, 10% owner · Common StockBought 2 750 762 @ $4,24$11,7M · 2025-11-25
Manning Paul BDirector, 10% owner · Common StockBought 1 375 380 @ $4,24$5,8M · 2025-11-25
Rieger JaysonDirector, CEO and President · Common StockBought 94 311 @ $4,24$400K · 2025-11-25

Short positioning

315.8Kshares short-2.7% vs prior

11.07days to cover

58.4%short of daily vol

5fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

VRCA.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Net margin (FY 2025-12-31): -50.3%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 370.2%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 88.6%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 88.6%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -65.0%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.9%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 350.9%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -25.2%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 81.5%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 71.1%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 76.6%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -34.9%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -100.0%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.90xDerived (calculated)
Current ratio (FY 2025-12-31): 2.59xDerived (calculated)
Return on assets (FY 2025-12-31): -38.0%Derived (calculated)
Return on equity (FY 2025-12-31): -72.3%Derived (calculated)
Total assets (annual): USD 47.13MSEC XBRL filing
Total liabilities (annual): USD 22.39MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
R&D expense (annual): USD 8.86MSEC XBRL filing
Capex (annual): USD 0SEC XBRL filing
Operating income (annual): USD -12.19MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-09FILING8-K filing →

2026-06-05 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative

2026-06-05INSIDERRosenberg Noah L. acquired 233.8k sh Employee Stock Option (right to buy) — CMO

2026-06-05INSIDERRieger Jayson acquired 512.3k sh Employee Stock Option (right to buy) — Director, CEO and President

2026-06-05INSIDERCorcoran Gavin acquired 16.0k sh Stock Option (right to buy) — Director

2026-06-05INSIDEREichenfield Lawrence acquired 16.0k sh Stock Option (right to buy) — Director

2026-06-05INSIDERNguyen Diem acquired 16.0k sh Stock Option (right to buy) — Director

2026-06-05INSIDERPRYGOCKI MARK A SR acquired 16.0k sh Stock Option (right to buy) — Director

2026-06-05INSIDERZawitz David acquired 171.3k sh Employee Stock Option (right to buy) — Chief Operating Officer

2026-05-12FILING10-Q filing →

2026-05-12FILING8-K filing →

2026-04-20FILINGDEF 14A filing →

2026-03-11FILING10-K filing →

2026-03-11FILING8-K filing →

2025-12-30FILING8-K filing →

2025-12-23 00:00 UTCINSIDER1 insider transaction — 2025-12

2025-12-23FILING424B3 filing →

2025-12-23INSIDERKirby John J. transacted 10.0k sh — Interim CFO

2025-11-25 00:00 UTCINSIDER12 insider transactions — 2025-11 · net buy $18.0M 6 derivative

2025-11-25INSIDERRosenberg Noah L. bought 2.4k sh — CMO ~$10k

2025-11-25INSIDERZawitz David bought 10.0k sh — Chief Operating Officer ~$42k

2025-11-25INSIDERKirby John J. bought 3.5k sh — Interim CFO ~$15k

2025-11-25INSIDERManning Paul B bought 2.75M sh — Director, 10% owner ~$11.67M

2025-11-25INSIDERManning Paul B bought 1.38M sh — Director, 10% owner ~$5.84M

2025-11-25INSIDERRieger Jayson bought 94.3k sh — Director, CEO and President ~$400k

2025-11-25INSIDERRieger Jayson acquired 23.6k sh Series C Warrant (right to buy) — Director, CEO and President

2025-11-25INSIDERZawitz David acquired 2.5k sh Series C Warrant (right to buy) — Chief Operating Officer

2025-11-25INSIDERKirby John J. acquired 884 sh Series C Warrant (right to buy) — Interim CFO

2025-11-25INSIDERRosenberg Noah L. acquired 589 sh Series C Warrant (right to buy) — CMO

2025-11-25INSIDERManning Paul B acquired 343.8k sh Series C Warrant (right to buy) — Director, 10% owner

2025-11-25INSIDERManning Paul B acquired 687.7k sh Series C Warrant (right to buy) — Director, 10% owner

2025-11-24FILING8-K filing →

2025-11-14FILING10-Q filing →

2025-11-14FILING8-K filing →

2025-08-12FILING10-Q filing →

2025-06-05 00:00 UTCINSIDER4 insider transactions — 2025-06 4 derivative

2025-03-31 00:00 UTCINSIDER3 insider transactions — 2025-03 3 derivative

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread